Reviewing Exact Sciences (NASDAQ:EXAS) & Grail (NASDAQ:GRAL)

Exact Sciences (NASDAQ:EXAS) and Grail (NASDAQ:GRAL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Valuation & Earnings

This table compares Exact Sciences and Grail’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exact Sciences	$2.61 billion	4.24	-$204.15 million	($1.32)	-45.46
Grail	N/A	N/A	N/A	N/A	N/A

Grail has lower revenue, but higher earnings than Exact Sciences.

Insider & Institutional Ownership

88.8% of Exact Sciences shares are held by institutional investors. 1.4% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Exact Sciences and Grail’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Exact Sciences	-6.70%	-4.97%	-2.41%
Grail	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and price targets for Exact Sciences and Grail, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exact Sciences	0	0	15	0	3.00
Grail	0	0	0	0	N/A

Exact Sciences currently has a consensus target price of $78.50, suggesting a potential upside of 30.81%. Given Exact Sciences’ higher possible upside, research analysts clearly believe Exact Sciences is more favorable than Grail.

Summary

Exact Sciences beats Grail on 5 of the 8 factors compared between the two stocks.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

About Grail

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.